Abstract
Differential diagnosis of dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD) and other dementias is essential for better management. Metaiodobenzylguanidine (MIBG) is a physiological analogue of norepinephrine, and 123I-MIBG myocardial scintigraphy has been used as a noninvasive tool for estimating myocardial sympathetic nerve damage due to various disorders such as heart and neurologic diseases. Degeneration of the cardiac sympathetic nerves is a neuropathological feature of Lewy body diseases including Parkinson’s disease and DLB. Multiple single-center studies, including ours, reported very high sensitivity and specificity of 123I-MIBG myocardial scintigraphy for the differential diagnosis of DLB from AD and other dementias; further, our first multicenter study of DLB with the standardized technique [1] substantiated the high diagnostic accuracy of 123I-MIBG myocardial scintigraphy, which was comparable to that of 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) SPECT multicenter study [2]. In the current version of the consensus diagnostic criteria for DLB [3], 123I-FP-CIT SPECT was listed as one of the suggestive features of DLB, whereas 123I-MIBG myocardial scintigraphy was listed as one of the supportive features. As 123I-MIBG myocardial scintigraphy has been proved to have high diagnostic specificity, it is recommended to upgrade the abnormal MIBG myocardial scintigraphy to one of the suggestive features of DLB.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yoshita M, Arai H, Arai T, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One. 2015;10:e0120540.
McKeith I, O’Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.
McKeith I, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863–72.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–24.
Lopez OL, Becker JT, Kaufer DI, et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol. 2002;59:43–6.
McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54:1050–8.
Ferman TJ, Boeve BF, Smith GE, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011;77:875–82.
Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129–32.
Dae MW, O’Connell JW, Botvinick EH, et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation. 1989;79:634–44.
Glowniak JV, Turner FE, Gray LL, et al. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med. 1989;30:1182–91.
Nakajima K, Bunko H, Taki J, et al. Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J. 1990;119:1329–37.
Hakusui S, Yasuda T, Yanagi T, et al. A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1994;49:81–4.
Iwasa K, Nakajima K, Yoshikawa H, et al. Decreased myocardial 123I-MIBG uptake in Parkinson’s disease. Acta Neurol Scand. 1998;97:303–6.
Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998;155:60–7.
Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol. 1997;38 Suppl 2:2–7.
Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology. 1999;52:1269–71.
Orimo S, Ozawa E, Oka T, et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology. 2001;57:1140–1.
Orimo S, Oka T, Miura H, et al. Sympathetic cardiac denervation in Parkinson’s disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2002;73:776–7.
Mitsui J, Saito Y, Momose T, et al. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci. 2006;243:101–4.
Orimo S, Uchihara T, Nakamura A, et al. Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain. 2008;131:642–50.
Orimo S, Nakamura A, Uchihara T, et al. Relationship among degeneration of the cardiac sympathetic nerve, clinical features and neuropathological findings in dementia with Lewy bodies. Neuropathology. 2012;32 Suppl:62.
Mori H, Oda M, Komori T, et al. Lewy bodies in progressive supranuclear palsy. Acta Neuropathol. 2002;104:273–8.
Orimo S, Kanazawa T, Nakamura A, et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol. 2007;113:81–6.
Nakajima K, Yoshita M, Matsuo S, et al. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging. 2008;52:378–87.
Okuda K, Nakajima K, Hosoya T, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18:82–9.
Nakajima K, Okuda K, Matsuo S, et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging. 2012;39:113–19.
Nakajima K, Okuda K, Yoshimura M, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21:970–8.
Hirayama M, Hakusui S, Koike Y, et al. A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1995;53:230–4.
Yoshida M, Fukumoto Y, Kuroda Y, et al. Sympathetic denervation of myocardium demonstrated by 123I-MIBG scintigraphy in pure progressive autonomic failure. Eur Neurol. 1997;38:291–6.
Yoshita M, Hayashi M, Hirai S. Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinson’s disease. Nucl Med Commun. 1998;19:137–42.
Orimo S, Ozawa E, Nakade S, et al. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67:189–94.
Goldstein DS, Holmes C, Li ST, et al. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med. 2000;133:338–47.
Yoshita M. Value of MIBG in the differential diagnosis of neurodegenerative disorders. In: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, Leenders KL, editors. PET and SPECT in neurology. New York/Berlin/Heidelberg: Springer; 2014. p. 437–49.
Miyamoto T, Miyamoto M, Inoue Y, et al. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology. 2006;67:2236–8.
Solanki KK, Bomanji J, Moyes J, et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13:513–21.
Yoshita M, Taki J, Yamada M. A clinical role for [123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001;71:583–8.
Watanabe H, Ieda T, Katayama T, et al. Cardiac 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2001;70:781–3.
Oide T, Tokuda T, Momose M, et al. Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer’s disease and dementia with Lewy bodies. Intern Med. 2003;42:686–90.
Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology. 2006;66:1850–4.
Hanyu H, Shimizu S, Hirao K, et al. The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord. 2006;22:379–84.
Hanyu H, Shimizu S, Hirao K, et al. Comparative value of brain perfusion SPECT and [123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2006;33:248–53.
Wada-Isoe K, Kitayama M, Nakaso K, et al. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci. 2007;260:33–7.
Inui Y, Toyama H, Manabe Y, et al. Evaluation of probable or possible dementia with lewy bodies using 123I-IMP brain perfusion SPECT, 123I-MIBG, and 99mTc-MIBI myocardial SPECT. J Nucl Med. 2007;48:1641–50.
Estorch M, Camacho V, Paredes P, et al. Cardiac 123I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging. 2008;35:1636–41.
Novellino F, Bagnato A, Salsone M, et al. Myocardial 123I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD. Neurobiol Aging. 2010;31:1903–11.
Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging. 2012;22:111–17.
Schmidt SL, Correa PL, Tolentino JC, et al. Value of combining activated brain FDG-PET and cardiac MIBG for the differential diagnosis of dementia: differentiation of dementia with Lewy bodies and Alzheimer disease when the diagnoses based on clinical and neuroimaging criteria are difficult. Clin Nucl Med. 2008;33:398–401.
Sakamoto F, Shiraishi S, Yoshida M, et al. Diagnosis of dementia with Lewy bodies: diagnostic performance of combined 123I-IMP brain perfusion SPECT and 123I-MIBG myocardial scintigraphy. Ann Nucl Med. 2014;28:203–11.
Camacho V, Marquié M, Lleó A, et al. Cardiac sympathetic impairment parallels nigrostriatal degeneration in probable dementia with Lewy bodies. Q J Nucl Med Mol Imaging. 2011;55:476–83.
Treglia G, Cason E, Cortelli P, et al. Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques? J Neuroimaging. 2014;24:149–54.
Noguchi-Shinohara M, Tokuda T, Yoshita M, et al. CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer’s disease. Brain Res. 2009;28:1–6.
Fujishiro H, Nakamura S, Kitazawa M, et al. Early detection of dementia with Lewy bodies in patients with amnestic mild cognitive impairment using 123I-MIBG cardiac scintigraphy. J Neurol Sci. 2012;315:115–19.
Oda H, Ishii K, Terashima A, et al. Myocardial scintigraphy may predict the conversion to probable dementia with Lewy bodies. Neurology. 2013;81:1741–5.
Chui HC, Lyness SA, Sobel E, et al. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer’s disease. Arch Neurol. 1994;51:676–81.
Attems J, Quass M, Jellinger KA. Tau and α-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol. 2007;113:53–62.
White L. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis. 2009;18:713–25.
Acknowledgments
The study was supported by the grant of Japan Foundation for Neuroscience and Mental Health (to M. Yamada). The funder had no role in preparation of the manuscript. The authors thank Ms. Etsuko Tsujiguchi for her secretarial assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Japan KK
About this chapter
Cite this chapter
Yamada, M., Yoshita, M., Samuraki, M., Komatsu, J., Nakajima, K. (2017). 123I-Metaiodobenzylguanidine Myocardial Scintigraphy in Dementia with Lewy Bodies. In: Kosaka, K. (eds) Dementia with Lewy Bodies. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55948-1_12
Download citation
DOI: https://doi.org/10.1007/978-4-431-55948-1_12
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55946-7
Online ISBN: 978-4-431-55948-1
eBook Packages: MedicineMedicine (R0)